Version 2.78

Description

Lung cancer has the highest mortality of all cancers across the world. Survival rates are much improved if the cancer is diagnosed and treated before the malignant cells have metastasized. Patients diagnosed with stage 1 lung cancer experience a 5-year survival rate of 52% which increases to 87.5% if platinum-based chemotherapy is part of the treatment. While computed tomography (CT) scans are the gold standard for diagnosing lung cancer, CT has a 50% rate of false positives and, subsequently, a large number of unnecessary follow-up treatments. An immunoassay has been developed that measures autoantibodies to lung cancer related antigens in the peripheral blood and may help lower the false positive rates of CT scans. These antibodies include CAGE, GBU4-5, NY-ESO-1, p53, SOX-2, MAGE A4, and HuD and one or more of them are present in 40% of patients at the time lung cancer is diagnosed. Which antibodies are positive may in the future provide a clue to what subtype of lung cancer the patient has developed. Ongoing studies are investigating the utility of the antibodies being used as biomarkers for lung cancer in high risk asymptomatic patients. There is also research investigating the changes in an individual's lung cancer antibody profile from their baseline values to predict early lung cancer development. PMID: 21733826 Source: Regenstrief LOINC

Basic Part Properties

Part Display Name
Lung cancer antibody panel
Part Type
Component (Describes the core component or analyte measured)
Created On
2018-03-09
Construct for LOINC Short Name
Lung cancer antibody panel

LOINC Terminology Service (API) using HL7® FHIR® Get Info

CodeSystem lookup
https://fhir.loinc.org/CodeSystem/$lookup?system=http://loinc.org&code=LP266490-4

Language Variants Get Info

Tag Language Translation
it-IT Italian (Italy) Cancro al polmone, panel anticorpi
Synonyms: Panel anticorpi cancro al polmone
zh-CN Chinese (China) 肺癌抗体组套
Synonyms: 肺癌抗体组套(组合、医嘱组、套餐、套餐医嘱、医嘱套餐、组合申请、组合项目)
es-ES Spanish (Spain) Perfil de anticuerpos contra el cáncer de pulmón